Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter 2026 (ended March 31, 2026)
Filing Date: May 12, 2026
Context: The filing incorporates a press release announcing Q1 2026 financial results, highlighting substantial sales growth for the ProSense® product in the U.S. and North America.
Key Financial Metrics
The provided text is a cover sheet for Form 6-K and does not contain specific numerical data. The following metrics are referenced in the press release title but are not quantified in this document:
- Revenue: Not specified in this text; press release indicates substantial increase in ProSense® sales.
- Profit/Loss: Not specified.
- Cash Flow: Not specified.
- Margins: Not specified.
- Debt and Liquidity: Not specified.
Note: The filing text does not provide clear values for these metrics; they are contained within the referenced Exhibit 99.1 (Press Release).
Material Changes
Sales Growth: The press release title indicates a substantial increase in ProSense® sales within the U.S. and North America compared to prior periods. Specific comparative figures are not present in this document.
Guidance, Outlook, and Risks
Management Commentary: The primary focus of the announcement is the commercial performance of the ProSense® product line in key geographic markets.
Guidance and Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Verify the specific revenue figures and percentage growth for ProSense® in the U.S. and North America by reviewing Exhibit 99.1 (the full press release).
- Confirm the company's cash position and burn rate, as these are not disclosed in the cover sheet.
- Review the full press release for any updated financial guidance or operational milestones for the remainder of 2026.
- Check for any material changes in the regulatory status of ProSense® that may have driven the reported sales increase.